Brief: Ac Immune’S Alzheimer’S Disease Vaccine-Candidate Selected For Further Development
30/11/2022 12:20
Nov 30 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE’S ALZHEIMER’S DISEASE VACCINE-CANDIDATE
ACI-35.030
SELECTED FOR FURTHER DEVELOPMENT
* AC IMMUNE SA - DATA PRESENTED AT CTAD 2022 CONFIRM
EXCELLENT
CLINICAL PERFORMANCE OF ACI-35.030 VACCINE CANDIDATE
Source text for Eikon: ID:nGNX8bbLKy
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health